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March 2010784 Abstractsscreening. Cost-effectiveness becomes more favorable overtime. Repeat
screening of patients whose initial scan result is normal is not justified.
Summary: The United Kingdom Multicentre Aneurysm Screening
Study (MASS) has provided most of the randomized evidence for mortality
benefit for AAA screening (Cochrane Database Syst Rev 2007;CD002945)
The authors sought to answer some remaining questions concerning AAA
screening, including longer-term benefits of mortality and cost-effectiveness,
and whether rescreening after a normal scan result is indicated. The data
presented are from the randomized MASS trial with 10 years of follow-up.
Data were acquired in four centers in the United Kingdom, with screening
and surveillance delivered primarily in primary care centers. The population
sample included 67,770men aged 65 to 70 years. Participants in the original
MASS study were allocated to ultrasound screening or to a control group
not offered screening. When an AAA was detected, the participants under-
went surveillance and were offered surgery if they met prespecified criteria.
Main outcomemeasures have beenmortality and costs related to AAA repair
and cost per life-year gained.
There were 155 deaths related to AAA over 10 years in the group
invited for screening (absolute risk, 0.46%) and 296 deaths related to AAA in
the control group (0.87%). Relative risk reduction was 45% (95% confidence
interval [CI], 37%-57%). The benefits seen in the early years of follow-up
were maintained in later years. Incremental cost per man invited to screening
was £100 (95% CI, £82-£118), with an incremental cost-effectiveness ratio
of £7,600 (95% CI, £5,100-£13,000) per life-year gained. The incidence of
ruptured AAA in patients with an originally normal screening result in-
creased after 8 years. Total mortality at 10 years was about 30% in each
group, with AAAs comprising about 2% of all deaths. There was no clear
difference in any other cause of death, with only a small difference in
all-cause mortality (hazard risk, 0.97, 95% CI, 0.95-1.00).
There were 25 ruptures that occurred after men had normal initial scan
results and 19 were fatal. Rate of ruptures increased noticeably after 8 years
of follow-up. Time since initial scan rather than age was the main determi-
nant of the increased risk of rupture.
Comment: AAA screening appears to be effective in reducing AAA-
related deaths out to 10 years after the initial screening examination. A
crucial question is whether rescreening participants is justified at any stage.
The authors contend that rescreening is not justified because the number of
fatal ruptures occurring after 8 years in the screened group was relatively
small. Additional follow-up will be required to determine if there is a
noticeable increase in ruptures in the screened group that is not sufficiently
offset by the reduction in number of deaths related to the original aortic
aneurysm screening.Short-term Outcomes of Borderline Stenoses in Vascular Accesses with
PTFE Grafts
Tuka V, Slavikova M, Krupickova Z, et al. Neph Dialysis Transplant 2009;
24:3193-7.
Conclusion: Borderline stenoses associated with polytetrafluoroethyl-
ene (PTFE) dialysis access grafts can be safely followed up and do not require
transluminal angioplasty.
Summary: The authors previously performed a randomized trial indi-
cating ultrasound surveillance significantly prolongs patency of PTFE dial-
ysis access grafts (Kidney Int 2005;65:1554-8). They identified certain
stenoses they termed “borderline.” They believed a “watch and wait”
strategy for such stenoses that were asymptomatic was appropriate but had a
relatively small number of patients in the original study. The present study
tested the hypothesis that it is safe to delay treatment of borderline stenoses
in patients without evidence of impaired dialysis function. They also sought
to determine possible risk factors for progression of such stenoses and the
long-term outcomes of such lesions. A stenosis of a PTFE dialysis access graft
was classified as significant if a there was50% lumen reduction on B-mode
imaging and a peak systolic velocity (PSV) ratio (PSV within the stenoses/
PSV in an adjacent unaffected prestenotic segment) of 2. In addition, a
residual diameter of 2 mm, blood flow of 600 ml/min, or blood flow
reduction of 25% was required for the stenoses to be considered signifi-
cant. Borderline stenoses have a50% lumen reduction by B-mode imaging
and a PSV 2, but none of the other additional criteria noted above.
The authors identified 102 borderline stenoses. After 11 6 weeks, 55
remained nonprogressive and 38 progressed. Eight underwent percutane-
ous transluminal angioplasty (PTA) for a clinical indication, and only one
graft thrombosed. Risk factors for developing significant stenosis in previ-
ously borderline lesions included prior PTA (relative risk, 1.91; 95% confi-
dence interval [CI], 1.27-2.88; P  .002), and female gender was a risk for
increasing stenosis (relative risk, 2.29; 95% CI, 1.29-4.06; P  .025).
Comment: The data indicate, at least using the definition provided by
the authors, that borderline stenoses remain stable for approximately 3
months and delaying treatment is safe when clinical monitoring is per-
formed. Most of the stenoses in this study did progress, however, and
median follow-up was only 3 months. The authors’ approach has the
possibility of reducing, in the short-term, the number angioplasties per-
formed for PTFE dialysis access grafts, but it is unclear if it will extend the
useful life a PTFE access before it must be abandoned for a new access graft
or access site.
